GlassScriptPhysician profile
Akshitha Yarrabothula
NPI 1144859471
$3,683.26
in general payments reported to CMS, 2019-2025
11 companies · $2,926 in 2025
The $2,926 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.54 · 2023: $154 · 2024: $591 · 2025: $2,926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,264 · Travel and Lodging: $1,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,263.96 |
| Travel and Lodging | $1,406.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,285.20 | 2024-2025 | Prostar, Perclose Prostyle, Ultreon |
| Boston Scientific Corporation | $480.26 | 2023-2025 | Avvigo Guidance System, Watchman Access System |
| Edwards Lifesciences Corporation | $284.14 | 2024-2025 | Pascal, Sapien 3 Ultra Resilia |
| Amgen INC. | $225.20 | 2024-2025 | Repatha, Repatha |
| Medtronic, INC. | $151.01 | 2024 | Corevalve Evolut R, Hawkone |
| Astrazeneca Pharmaceuticals LP | $89.36 | 2023-2025 | Andexxa, Wainua |
| Pfizer INC. | $44.37 | 2021-2025 | |
| Kestra Medical Technology Services, INC. | $38.87 | 2025 | Assure Wcd |
| Bridgebio Pharma, INC. | $34.26 | 2025 | Attruby |
| Novartis Pharmaceuticals Corporation | $29.32 | 2025 | |
| Lantheus Medical Imaging, INC. | $21.27 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akshitha Yarrabothula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.